Patents by Inventor Michael Ming-Jin Poe

Michael Ming-Jin Poe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS
    Publication number: 20240083905
    Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.
    Type: Application
    Filed: August 2, 2023
    Publication date: March 14, 2024
    Inventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
  • Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAreceptor agonists
    Patent number: 11753412
    Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: September 12, 2023
    Assignees: UWM Research Foundation, Inc., Centre for Addiction and Mental Health, University of Belgrade—Faculty of Pharmacy
    Inventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
  • TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS
    Publication number: 20210309662
    Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.
    Type: Application
    Filed: December 15, 2020
    Publication date: October 7, 2021
    Inventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
  • Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists
    Patent number: 10906909
    Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: February 2, 2021
    Assignees: UWM Research Foundation, Inc., Centre for Addiction and Mental Health, University of Belgrade—Faculty of Pharmacy
    Inventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
  • TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS
    Publication number: 20200181146
    Abstract: Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.
    Type: Application
    Filed: March 20, 2017
    Publication date: June 11, 2020
    Inventors: James M. Cook, Guanguan Li, Michael Ming-Jin Poe, Miroslav M. Savic, Etienne Sibille
  • GABAERGIC LIGANDS AND THEIR USES
    Publication number: 20190300534
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: February 25, 2019
    Publication date: October 3, 2019
    Inventors: James M. Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • Gabaergic ligands and their uses
    Patent number: 10259815
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 16, 2019
    Assignee: UWM Research Foundation, Inc.
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • GABAERGIC LIGANDS AND THEIR USES
    Publication number: 20180065967
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 8, 2018
    Inventors: James Cook, Michael Ming-Jin Poe, Kashi Reddy Methuku, Guanguan Li
  • GABAergic receptor subtype selective ligands and their uses
    Patent number: 9597342
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: March 21, 2017
    Assignee: UWM Research Foundation, Inc.
    Inventors: James M. Cook, Terry S. Clayton, Hiteshkumar D. Jain, Yun Teng Johnson, Jie Yang, Sundari K. Rallipalli, Zhi-jian Wang, Ojas A. Namjoshi, Michael Ming-Jin Poe
  • GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES
    Publication number: 20150258128
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: March 3, 2015
    Publication date: September 17, 2015
    Inventors: James M. Cook, Terry S. Clayton, Hiteshkumar D. Jain, Yun Teng Johnson, Jie Yang, Sundari K. Rallipalli, Zhi-jian Wang, Ojas A. Namjoshi, Michael Ming-Jin Poe
  • Gabaergic receptor subtype selective ligands and their uses
    Patent number: 9006233
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: April 14, 2015
    Assignee: UWM Research Foundation, Inc.
    Inventors: James M. Cook, Terry S. Clayton, Hiteshkumar D. Jain, Sundari K. Rallipalli, Yun Teng Johnson, Jie Yang, Michael Ming-jin Poe, Ojas A. Namjoshi, Zhi-jian Wang
  • GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES
    Publication number: 20120295892
    Abstract: Described herein are ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as ?3 or ?2 or ?2/?3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 22, 2012
    Applicant: UWM RESEARCH FOUNDATION, INC.
    Inventors: James M. Cook, Terry S. Clayton, Hiteshkumar D. Jain, Sundari K. Rallipalli, Yun Teng Johnson, Jie Yang, Michael Ming-Jin Poe, Ojas A. Namjoshi, Zhi-jian Wang